You are here: Industry Insights > metastatic breast cancer

News List

NCCN, Pfizer Announces Funding for Metastatic Breast Cancer Projects americanpharmaceuticalreview
December 16, 2019
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced the proposals that were selected to receive funding ...
SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer drugs
December 12, 2019
Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with ...
Labcorp, QIAGEN announce companion diagnostic for metastatic breast cancer biospectrumasia
June 11, 2019
Piqray, in combination with fulvestrant, and therascreen PIK3CA PCR mutation analysis assay received approval from the U.S. Food and Drug Administration (FDA) on May 24, 2019.
Labcorp, QIAGEN announce companion diagnostic for metastatic breast cancer biospectrumasia
June 10, 2019
Piqray, in combination with fulvestrant, and therascreen PIK3CA PCR mutation analysis assay received approval from the U.S. Food and Drug Administration (FDA) on May 24, 2019.
FDA approves Novartis' Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer cphi-online
March 20, 2017
Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumour location.
The Union for International Cancer Control and Pfizer announce next phase of global grants initiativ worldpharmanews
March 10, 2017
In conjunction with International Women's Day, The Union for International Cancer Control (UICC) and Pfizer Inc. have announced the next phase of their pioneering grants initiative to address the unique challenges facing metastatic breast cancer (mBC) pat
Clinigen and Eisai partner to offer Halaven for metastatic breast cancer in South Africa pharmaceutical-technology
March 01, 2017
Japanese pharmaceutical company Eisai has partnered with UK-based pharmaceutical and services firm Clinigen Group to distribute Halaven (eribulin) in South Africa for the treatment of women with metastatic breast cancer.
Lynparza Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer americanpharmaceuticalreview
February 20, 2017
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative